Ciliary neurotrophic factor not checked
Neurotech Pharmaceuticals · NT-501
FollowEvery change as it happens, and a Monday email
Trials
2 active
10 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NT-501 is surgically implanted into the vitreous cavity to continuously release recombinant human ciliary neurotrophic factor (CNTF).”In the company’s words, NCT06971939 on ClinicalTrials.gov
- Tested for
- Macular Telangiectasia Type 2 (MacTel), Macular Telangiectasia Type 2
- Main trialPhase 4
- “The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study and have retained at least 1 NT-501 at study entry. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect…”In the company’s words, NCT06971939 on ClinicalTrials.gov
- Other names
- NT-501 · CNTF · Encapsulated Cell Therapy · ECT · CNTF implant · ENCELTO · M-CHFM · CHFM
Other drugs for Macular Telangiectasia Type 2
- Surabgene LomparvovecAbbVie · Phase 3
- IRX-101iRenix Medical, Inc. · Phase 3
- 4D-150 IVT4D Molecular Therapeutics · Phase 3
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- ElamipretideStealth BioTherapeutics Inc. · Phase 3
Coming up2
- 1 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Jan 2032Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 15 Jan 2032 | Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants | |
| Phase 3Recruiting | 1 May 2028 | A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM | |
| Phase 3Completed | 31 Aug 2022 | A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A | |
| Phase 3Completed | 31 Aug 2022 | A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B | |
| Phase 2Completed | 11 May 2009 | A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration | |
| Phase 2Completed | 26 May 2009 | A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa | |
| Phase 2Completed | 19 Apr 2010 | A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa | |
| Phase 2Completed | 1 Jul 2019 | Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa | |
| Phase 2Completed | 11 May 2021 | Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) | |
| Phase 2Completed | 8 Dec 2022 | Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026